Curated research links

Preclinical characterization of an NNMT inhibitor in diet-induced obesity (related to 5-Amino-1MQ pharmacology).

Review summarizing BPC-157 preclinical wound-healing and tissue-protection literature.

Original rat Achilles transection study reporting accelerated tendon healing.

Cochrane assessment concluding insufficient evidence to determine effect on death or dependency in stroke.

Clinical pharmacology of CJC-1295 DAC demonstrating extended GH/IGF-1 elevation in healthy adults.

Comprehensive review of GHK-Cu — a common constituent of KLOW and GLO blends.

Phase 2b trial of larazotide acetate — a constituent listed in some GLO formulations.

Original characterization of ipamorelin's selectivity versus earlier GHS peptides.

Comprehensive review of GHK-Cu — a common constituent of KLOW and GLO blends.

Original description of MOTS-c and its effects on insulin sensitivity in rodent models.

Review of NAD+ and precursor pharmacology — the best starting point for NAD+/NR/NMN biology.

Phase 3b cardiovascular outcomes trial — first large CV benefit signal for semaglutide.

Pivotal Phase 3 weight-management trial — 14.9% mean weight reduction at 68 weeks.

Extended CV benefit of semaglutide beyond diabetes, in adults with overweight/obesity.

Mechanism study linking Semax to BDNF expression changes in rat brain regions.

Review of sermorelin pharmacology and historical clinical use.

Foundational review of thymosin β4 biology — the parent protein of the TB-500 fragment.

Head-to-head Phase 3 showing larger A1C and weight reduction for tirzepatide.

~20% mean weight reduction at the highest dose — the largest Phase 3 weight-loss effect reported to date in a pharmacotherapy.

Clinically meaningful apnea-hypopnea index reduction; expanded indication.